For her part, Silver experienced some mild nausea and occasional headaches during the first few weeks on the medication
The combination arm was terminated early due to severe adverse events and deaths, while NAC alone showed no significant effect on lung function, though secondary endpoints (6MWD, QoL) improved modestly (139)
Seek immediate medical attention for: Severe, persistent abdominal pain, especially if different from typical IBS pain or radiating to the back (possible pancreatitis) Persistent vomiting preventing adequate fluid intake Signs of dehydration (decreased urination, dizziness, extreme thirst) Severe constipation lasting more than 3-4 days without bowel movement Blood in stool or black, tarry stools Yellowing of skin/eyes, right upper quadrant pain (possible gallbladder disease) Markedly reduced urination (possible acute kidney injury) Fever accompanying gastrointestinal symptoms Neck mass, difficulty swallowing, persistent hoarseness (thyroid concerns) Allergic reactions (rash, itching, swelling, severe dizziness) Scheduled follow-up should occur within 4-6 weeks of initiating therapy and after each dose escalation
Cagrilintide is not designated for medical, diagnostic, or therapeutic applications
Major weight loss most likely will not occur in the first week of treatment with a GLP-1
